13.3 Recommending Treatment Modifications

12.3 Recommending Treatment Modifications

Quick Answer: When monitoring shows therapy is off target or unsafe, recommend a specific modification: change dose, switch, deprescribe, add monitoring, refer, or optimise non-drug care. Base advice on evidence + patient values + clinical status, communicate collaboratively, plan titration or taper, and document rationale. Abrupt stops of benzodiazepines or beta-blockers can be dangerous—use structured withdrawal thinking.

Section 13.1 finds problems; Section 13.2 interprets data; this section turns findings into actionable recommendations—the decision-making heart of Standard 3.3.

When modification is indicated

Consider change when one or more of the following is true:

• Goal not met after an adequate trial (dose, duration, adherence verified)
• Harm exceeds benefit (ADR, high-risk interaction, fall risk, cognitive impairment)
• Indication resolved or was never valid (candidate for deprescribing)
• Organ function changed (renal/hepatic decline requires dose or drug change)
• Life stage changed (pregnancy potential, frailty, palliative goals)
• Adherence barriers make the current regimen unworkable (complexity, cost, formulation)

Do not modify solely because a computer alert fired without clinical relevance, or because a single mild lab drift is expected and already managed.

The modification menu

Evidence and patient values

Best-practice recommendations weigh:

1. Evidence — guideline-directed options, AMH/APF-aligned dosing and cautions, known outcome data (for example prognostic pillars in HFrEF).
2. Clinical status — comorbidities, labs, allergies, interacting drugs.
3. Patient values — priorities (avoiding sexual side effects, preserving independence, cost, cultural preferences, fertility).
4. Practicality — regimen complexity, carer support, dose administration aids, PBS access realities.

A “guideline-perfect” regimen the patient will not take is a failed plan. Shared decisions may accept a slightly less intensive regimen that is actually used safely.

Communicating recommendations

Use a concise clinical structure when contacting prescribers or explaining to patients:

• Situation: who the patient is and the relevant therapy
• Background: indication, recent changes, adherence, key results
• Assessment: the prioritised drug-related problem
• Recommendation: specific, feasible next step with monitoring

Example tone: “Blood pressure remains above target on low-dose ACE inhibitor with good adherence; potassium and creatinine are stable. Suggest stepwise dose increase with repeat electrolytes/renal function, unless you prefer adding a CCB because of cough risk historically.”

Avoid vague statements (“maybe review meds sometime”) and avoid overstepping scope (“I have already stopped your specialist’s chemotherapy”). For prescription changes, recommend and facilitate—do not invent unlawful supply.

Stepwise titration examples

Antihypertensives

• Confirm technique, adherence, and white-coat issues before stacking drugs.
• Intensify in steps: optimise dose of first agent or add a second first-line class per individualised plan.
• Recheck BP response and electrolytes/renal function when ACEI/ARB/diuretic doses change.
• In older/frail patients, slower titration and fall-risk awareness matter as much as the millimetres of mercury.

Antidepressants — onset and adequate trial

• Many antidepressants need weeks for meaningful response; early adverse effects (nausea, activation, sexual dysfunction) may appear sooner.
• Do not label “treatment failure” after a few days of low-dose therapy without considering onset time, adherence, and dose optimisation.
• Discuss suicide risk monitoring early in therapy or after dose changes, especially in younger people—safety planning and urgent referral rules apply.
• Switching strategies (and any washout needs for particular classes) should follow evidence and specialist advice when complex.

Analgesics and other symptom-driven therapy

• Titrate to function and safety, not only pain scores.
• Step down when acute pain drivers resolve; prolonged high-dose opioids without review is a modification opportunity (deprescribe/taper plan with the prescriber).

Stopping high-risk medicines safely

Benzodiazepines and Z-drugs (concepts)

Long-term benzodiazepine use risks dependence, falls, and cognitive effects. Abrupt cessation after prolonged use can precipitate withdrawal (anxiety rebound, insomnia, tremor, in severe cases seizures). Safe approaches emphasise:

• Shared decision and gradual dose taper over an individualised period
• Possibly converting to a longer-acting agent in some specialist-guided strategies
• Non-drug sleep/anxiety supports
• Monitoring for withdrawal and relapse of original symptoms
• Avoiding simply “running out and stopping” without a plan

Intern exam items often test recognition that sudden stop is unsafe after chronic use, not the exact milligram schedule of every taper protocol.

Beta-blockers

Abrupt withdrawal of beta-blockers can be associated with rebound tachycardia, hypertension, or worsening angina in at-risk patients. When beta-blockers are to be stopped, gradual dose reduction under medical direction is the usual safety message—especially in ischaemic heart disease. Do not advise cold-turkey cessation for convenience when a prescription ends without review.

Other taper/rebound examples (awareness)

• Long-term systemic corticosteroids: adrenal insufficiency risk if stopped abruptly after significant exposure—specialist/medical taper plans.
• Some antidepressants: discontinuation symptoms if stopped suddenly—slow reduction often preferred.
• Anticonvulsants and other CNS medicines: seizure risk if stopped abruptly—never recommend unsupervised sudden cessation.

Deprescribing as a positive intervention

Deprescribing is planned withdrawal of medicines that are no longer beneficial or are harmful. Steps:

1. Agree the target medicine and goal (stop vs reduce)
2. Check dependence/rebound potential → taper vs stop
3. Sequence one major change at a time when possible
4. Provide symptomatic supports and non-drug alternatives
5. Book follow-up for efficacy, withdrawal, and recurrence
6. Update allergy/ADR records if a true reaction prompted the stop

Polypharmacy in older people is a frequent setting: anticholinergics, sedatives, long-term PPIs without indication, and duplicate therapies are common candidates—always individualise.

Document the rationale

Documentation should capture:

• Problem identified (linked to goal or harm)
• Evidence/clinical triggers (labs, symptoms, adherence findings)
• Options considered
• Recommendation made and to whom
• Patient understanding and preferences
• Monitoring and follow-up timing
• Outcome when known (closed loop)

Good records protect patients at handover and demonstrate Standard 3.3 competence. On the exam, the “best answer” usually pairs a safe specific action with communication and monitoring, not silent unilateral extremes.

Putting modifications into one clinical story

A patient on chronic diazepam, ramipril, and incomplete antidepressant response presents with falls and persistent low mood. Prioritise: assess sedation/fall contribution → collaborative benzodiazepine taper plan (not abrupt stop) → verify antidepressant dose/duration/adherence before declaring failure → check BP, renal function, potassium if intensifying ramipril later → document and follow up. That sequence is clinical review converted into safer therapy.

Treatment modification is where monitoring becomes care: choose the right change, make it safely, say it clearly, write it down, and check it worked.